Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (151-160 of 464) with videos related to

Pageof 47
Sort By:
Journal of Crohn'S & Colitis|August 25, 2022
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION StudyEdward V Loftus, Séverine Vermeire, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology|February 4, 2023
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G Feagan, Bruce E Sands, William J Sandborn, et al.
Gut|October 28, 2018
Definitions of response and remission for the Robarts Histopathology IndexRish K Pai, Reena Khanna, Geert R D'Haens, et al.
Gut|October 5, 2014
A phase II study of laquinimod in Crohn's diseaseGeert D'Haens, William J Sandborn, Jean Frederic Colombel, et al.
Advances in Therapy|March 21, 2025
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical TrialsYuki Otani, Brian G Feagan, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|September 30, 2017
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 8, 2020
Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With InfliximabNiels Vande Casteele, Vipul Jairath, Jenny Jeyarajah, et al.
Gastroenterology|August 19, 2008
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Richard N Fedorak, et al.
Digestive Diseases and Sciences|March 26, 2021
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic ReviewChristopher Ma, John K MacDonald, Tran M Nguyen, et al.
The American Journal of Gastroenterology|November 24, 2011
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statementsAlain Bitton, Donald Buie, Robert Enns, et al.
Pageof 47

Showing results (151-160 of 464) with videos related to

Sort By:
Pageof 47
Journal of Crohn'S & Colitis|August 25, 2022
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION StudyEdward V Loftus, Séverine Vermeire, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology|February 4, 2023
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trialBrian G Feagan, Bruce E Sands, William J Sandborn, et al.
Gut|October 28, 2018
Definitions of response and remission for the Robarts Histopathology IndexRish K Pai, Reena Khanna, Geert R D'Haens, et al.
Gut|October 5, 2014
A phase II study of laquinimod in Crohn's diseaseGeert D'Haens, William J Sandborn, Jean Frederic Colombel, et al.
Advances in Therapy|March 21, 2025
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical TrialsYuki Otani, Brian G Feagan, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|September 30, 2017
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 8, 2020
Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With InfliximabNiels Vande Casteele, Vipul Jairath, Jenny Jeyarajah, et al.
Gastroenterology|August 19, 2008
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Richard N Fedorak, et al.
Digestive Diseases and Sciences|March 26, 2021
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic ReviewChristopher Ma, John K MacDonald, Tran M Nguyen, et al.
The American Journal of Gastroenterology|November 24, 2011
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statementsAlain Bitton, Donald Buie, Robert Enns, et al.
Pageof 47